GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

Original source summary

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

Verbatim from News-Medical's own feed — "GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes"